Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: A repeat cross-sectional study

The Lancet Infectious Diseases

Volumn 14, Issue 10, 2014, Pages 958-966

  Tabrizi, Sepehr N ^a,b,c,d   Brotherton, Julia M L ^e,f   Kaldor, John M ^g   Skinner, S Rachel ^f   Liu, Bette ^h   Bateson, Deborah ⁱ   McNamee, Kathleen ^j,k   Garefalakis, Maria ^l   Phillips, Samuel ^a,d   Cummins, Eleanor ^a,d   Malloy, Michael ^e   Garland, Suzanne M ^a,b,c,d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e VICTORIAN CYTOLOGY SERVICE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ Family Planning New South Wales   (Australia)

^j Family Planning Victoria   (Australia)

^k MONASH UNIVERSITY   (Australia)

^l Family Planning Western Australia   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AUSTRALIA; CANCER RISK; COMPARATIVE STUDY; CROSS PROTECTION; CROSS-SECTIONAL STUDY; FAMILY PLANNING; FEMALE; HEALTH PROGRAM; HERD IMMUNITY; HORMONAL CONTRACEPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; NORMAL HUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; SCREENING TEST; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; ALPHAPAPILLOMAVIRUS; GENOTYPE; HEALTH CARE PLANNING; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; AUSTRALIA; CROSS PROTECTION; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEALTH PLAN IMPLEMENTATION; HUMANS; IMMUNITY, HERD; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; VACCINATION; YOUNG ADULT;

EID: 84908152101     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70841-2     Document Type: Article

References (38)

1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814.
2. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
3. Gertig DM, Brotherton JM, Saville M Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8:171-178.
4. Brotherton JM, Murray SL, Hall MA, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust 2013, 199:614-617.
5. Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Commun Dis Intell Q Rep 2011, 35:197-201.
6. Brotherton JM, Liu B, Donovan B, Kaldor JM, Saville M Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014, 32:592-597.
7. Laemmle-Ruff I, Barbaro B, Brotherton J Human papillomavirus vaccine national catch-up program-insights into under-notification. Aust Fam Physician 2013, 42:880-884.
8. Donovan B, Franklin N, Guy R Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
9. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87:544-547.
10. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
11. Cervical screening in Australia 2010-2011. AIHW cancer series, no. 76 2013, Australian Institute of Health and Welfare, Australian Institute of Health and Welfare, Canberra.
12. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
13. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013, 11:227.
14. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206:1645-1651.
15. Garland SM, Brotherton JM, Condon JR, et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 9:104. for the WHINURS study group.
16. Stevens MP, Rudland E, Garland SM, Tabrizi SN Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006, 44:2428-2433.
17. Papachristou E, Sypsa V, Paraskevis D, et al. Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test. J Med Virol 2009, 81:2059-2065.
18. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38:357-361.
19. Layton-Henry J, Scurry J, Planner R, et al. Cervical adenoid basal carcinoma, five cases and literature review. Int J Gynecol Cancer 1996, 6:193-199.
20. Stevens MP, Garland SM, Tabrizi SN Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods 2006, 135:124-126.
21. Stevens MP, Garland SM, Tabrizi SN Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 2008, 147:290-296.
22. Stevens MP, Garland SM, Tabrizi SN Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol 2008, 46:3813-3816.
23. Tabrizi SN, Stevens M, Chen S, Rudland E, Kornegay JR, Garland SM Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am J Clin Pathol 2005, 123:896-899.
24. Pink B Information paper 2039.0: an introduction to socio-economic indexes for areas (SEIFA) 2006 2008, Australian Bureau of Statistics, Australian Bureau of Statistics, Commonwealth of Australia, Canberra.
25. Rural, regional and remote health: a guide to remoteness classifications 2004, Australian Institute of Health and Welfare, Australian Institute of Health and Welfare, Canberra.
26. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
27. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014, 110:2804-2811.
28. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013, 32:26-32.
29. Deleré Y, Remschmidt C, Leuschner J, et al. Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014, 14:87.
30. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130:e249-e256.
31. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208:385-393.
32. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012, 30:5496-5499.
33. Rissel CE, Richters J, Grulich AE, de Visser RO, Smith AM Sex in Australia: first experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 2003, 27:131-137.
34. Smith A, Agius P, Mitchell A, Barrett C, Pitts M Secondary students and sexual health 2008: results of the 4th National Survey of Australian Secondary Students, HIV/AIDS and Sexual Health 2009, Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne.
35. Lim MS, Bowring AL, Gold J, Aitken CK, Hellard ME Trends in sexual behavior, testing, and knowledge in young people; 2006-2011. Sex Transm Dis 2012, 39:831-834.
36. Barbaro B, Brotherton JML Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?. Aust N Z J Public Health 2014, published online June 24. 10.1111/1753-6405.12218.
37. Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?. Vaccine 2013, 31:3928-3935.
38. Medical Services Advisory Committee (MSAC) recommendations Australian Government Department of Health, National Cervical Screening programNational Cervical Screening program, (accessed May 14, 2014). http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/ncsp-renewal.